A5047602325- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV-related health complications and treatments
- HIV/AIDS Research and Interventions
- Monoclonal and Polyclonal Antibodies Research
- Drug-Induced Hepatotoxicity and Protection
- Drug-Induced Adverse Reactions
- Viral gastroenteritis research and epidemiology
- Gut microbiota and health
- Phagocytosis and Immune Regulation
- Colorectal Cancer Treatments and Studies
- Liver physiology and pathology
- Medical Imaging and Pathology Studies
- Bacteriophages and microbial interactions
- Liver Disease and Transplantation
- Carbohydrate Chemistry and Synthesis
- Respiratory viral infections research
- Clostridium difficile and Clostridium perfringens research
Italian Medicines Agency
2018
Istituti di Ricovero e Cura a Carattere Scientifico
2004-2016
Policlinico San Matteo Fondazione
2004-2016
University of Pavia
2008-2014
<h3>Objective</h3> In patients with hepatitis C virus (HCV)/HIV co-infection, a faster progression of liver fibrosis to cirrhosis has been reported. this study, an investigation was carried out determine whether gp120, HIV envelope protein, modulates the biology human hepatic stellate cells (HSCs), key cell types in pathogenesis fibrosis. <h3>Methods</h3> Myofibroblastic HSCs were isolated from normal tissue. Gene expression measured by real-time PCR. Cell migration assessed Boyden chambers....
Background Dolutegravir plus darunavir provide a high genetic barrier to HIV-1 resistance and are suitable for simple salvage regimens. Methods All HIV-1-infected subjects treated with dolutegravir boosted dual therapy between March 2011 September 2015 were included in an observational cohort. Data collected at baseline weeks 4, 12, 24 48. Results We enrolled 113 subjects. After week 24, one was lost follow-up, dropped out grade 2 elevation of liver enzymes, died from illicit drug abuse...
Background and aims: The total health care cost for human immunodeficiency virus (HIV) patients has constantly grown in recent years. To date, there is no information about how this trend will behave over the next few aim of present study to define a pharmacoeconomic model forecast costs group chronically treated followed period 2004–2009. Methods: A pharmacoeconomics was built describe probability transition among different states modify therapy time. Markov applied evaluate temporal...